Wk 7 Natural Chemotherapy Agents Flashcards
Name of 2 topoisomerase I inhibitor
Irinotecan
Topotecan
-both are Camptothecins
2 Topoisomerase II inhibitors
- Doxorubicin (an anthracycline)
- Etoposide (an epipodophyllotoxin)
Microtubular targeting agents
Vincristine - a vinca alkaloid
Paclitaxel - a taxane
Antibiotic chemotherapy
Bleomycin
Selective estrogen receptor modulator
Tamoxifen
LHRH agonist
Goserelin
What are the ABCDEs of melanoma?
A = asymmetry
B = border
C = color
D = diameter
E = evolution (melanomas change rapidly, nevi usually don’t)
What is a nevi?
a neoplasm that’s usually benign
-increase risk of melanoma
-common
What are tx options for malignant melanoma?
Immunotherapy: anti-CTLA4, anti-PD1
BRAF inhibitors
Melanoma Risk Factors
-lighter pigmentation, sunburns at young age, more UV exposure
-worse melanoma-specific survival w/ African ancestry
-p16 loss (encoded at CDKN2A)
-spontaneous melanoma w/ BRAF-activating mutations (others: NRAS, KIT, TERT promotor mutations)
MOA of Topoisomerase I inhibitors
Topoisomerase I relaxes supercoiled dsDNA
-inhibitors bind DNA and topo I together until the DNA replication fork reaches the cleavable complex and causes dsDNA breaks
-S-phase specific
-resistance can occur from mutations in topo I, decreased intracellular retention or reduced [topo I]
MOA Irinotecan
AKA SN-38
-is a prodrug
-activated by carboxylesterdase in tissues and serum
-glucuronidation = breakdown pathway
-need to check for genetic polymorphism b/c can be highly toxic w/ breakdown pathway
Irinotecan Tox
Diarrhea
-neutropenia, mucositis, N/V, alopecia
MOA Topo II inhibitors
-Topo II unwinds supercoiled dsDNA
-inhibitors bind DNA and topo II together, making transient cleavable complexes continually cleavable, preventing re-ligation
-S-phase sensitive
-Resistance due to p-glycoprotein upregulation, increase in drug degradation, or decreased [topo II]
Etoposide
AKA VP-16
IV/PO
-hepatic metabolism
-renal excretion
AE: myelosuppression, delayed secondary malignancies
Anthracycline (Doxorubicin) MOA
Intercalates w/ DNA, interferes w/ uncoiling:
-interferes w/ topo II preventing strand reconnection
-intercalation alters shape, impairing repair enzymes
-forms free radicals ->cell structure damage
-Resistance due to P-glycoprotein, alteration of topo fxn, or decreased topo II
Doxorubicin AE, route
IV
-hepatic elimination
-cardiotoxicity (acute & chronic - lifetime exposure can -> CHF)
-myelosuppression, mucositis, extravasation necrosis, alopecia, emesis
-red urine
What med acts as a heart protectant for anthracyclines?
Dexrazoxane
-chelates iron in the heart (necessary for free radical damage)
-not ideal b/c takes 1 of 3 MOAs from the anthracyclines